Shares of Celsion (CLSN) soar 15.4% in premarket trading after the firm catches a Buy rating along with positive comments from Brean Murray on the strength of encouraging data it expects to see released on Celsion's ThermoDox treatment later this year. Analysts at Brean set a PT of $7 for CLSN - marking 267% upside potential.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs